Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6615 for symptomatic hypertrophic cardiomyopathy
NL-OMON42173Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing GS-6615 with Placebo (2 arms). Primary endpoints: Change in peak VO2 at Week 24 and Safety and tolerability. Started Sep 2015; status: active, not recruiting.
02
Drugs
eleclazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON42173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42173.